Active Ingredient

Active Substance: Miramistin monohydrate (0.01%) — a cationic antiseptic agent with a unique amphiphilic structure that integrates into microbial cell membranes, causing irreversible damage.

Key pharmacological properties:

• Broad-spectrum antimicrobial activity (gram-positive and gram-negative bacteria)
• Effective against a wide range of viruses and fungi
• No systemic toxicity — safe for mucous membranes
• Non-irritant; well-tolerated with repeated use
• Does not disrupt normal vaginal microflora at therapeutic concentrations

Clinical Indications & Therapeutic Uses

AVVASEPT Vaginal Douche is indicated for:

• Prevention and management of vaginitis
• Sexually transmitted disease (STD) prevention
• Postpartum care and hygiene
• Pre- and postoperative disinfection in gynaecological procedures

Proven antiseptic activity against the following pathogens:

• Candida species (Candidiasis)
• Trichomonas vaginalis (Trichomoniasis)
• Neisseria gonorrhoeae (Gonorrhoea)
• Chlamydia trachomatis (Chlamydia)
• Herpes simplex virus (HSV)
• Human papillomavirus (HPV)
• Staphylococcus aureus, Streptococcus spp., and other common pathogens

Clinical Data — Comparative Efficacy

The following table summarises the comparative efficacy of Miramistin monohydrate (the active ingredient in AVVASEPT) vs the most commonly used antiseptics, based on published clinical and laboratory data.

Reference: Ali Osmanov, Zara Farooq, Malcolm D Richardson, David W Denning. The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. FEMS Microbiology Reviews, Volume 44, Issue 4, July 2020, Pages 399–417. https://doi.org/10.1093/femsre/fuaa012

Safety Profile

AVVASEPT demonstrates an excellent safety profile, supported by clinical evidence:

• Non-irritant formulation safe for sensitive mucous membranes
• No systemic absorption — localised action only
• No reported development of clinically significant microbial resistance
• Compatible with vaginal tissue — does not alter normal flora at recommended dosage
• Suitable for use across different patient groups including postpartum patients

Presentation & Packaging

AVVASEPT Vaginal Douche is available in the following presentation:

• Volume: 150 mL intravaginal solution
• Applicator: Appropriate applicator included for ease of use
• Storage: Store below 25°C, away from direct light and out of reach of children

Market Context

According to Spherical Insights, the Global Antiseptics and Disinfectants Market Size was valued at USD 28.75 Billion in 2023. The market is growing at a CAGR of 10.67% from 2023 to 2033, with the worldwide Antiseptics and Disinfectants Market Size expected to reach USD 79.25 Billion by 2033. AVVASEPT is ideally positioned to capitalise on this high-growth segment.